NASDAQ:DRMA Dermata Therapeutics (DRMA) Stock Price, News & Analysis $1.02 -0.05 (-4.67%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$1.07 +0.05 (+4.90%) As of 10/9/2026 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsOwnershipSEC Filings About Dermata Therapeutics Stock (NASDAQ:DRMA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Dermata Therapeutics alerts:Sign Up Key Stats Today's Range$1.01▼$1.0850-Day Range$1.02▼$1.7252-Week Range$0.95▼$4.66Volume22,093 shsAverage Volume22,308 shsMarket Capitalization$4.10 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for dermatological diseases and conditions. The company’s research programs are designed to address areas of significant unmet need in medical dermatology, including inflammatory and other common skin disorders. Dermata’s lead product candidate has been DMT310, a topical treatment based on a proprietary technology derived from a freshwater sponge. The company has evaluated DMT310 for conditions including acne vulgaris and psoriasis, with development programs intended to assess its potential as a treatment for a range of skin diseases. Dermata Therapeutics was founded in 2014 and is headquartered in San Diego, California. The company completed its initial public offering in 2021 and has primarily operated as a development-stage business, with its activities centered on advancing its dermatology product candidates through clinical development and regulatory review.AI Generated. May Contain Errors. Read More Dermata Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks23rd Percentile Overall ScoreDRMA MarketRank™: Dermata Therapeutics scored higher than 23% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingDermata Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageDermata Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Dermata Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Dermata Therapeutics is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dermata Therapeutics is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDermata Therapeutics has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Dermata Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.69% of the float of Dermata Therapeutics has been sold short.Short Interest Ratio / Days to CoverDermata Therapeutics has a short interest ratio ("days to cover") of 3.61, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Dermata Therapeutics has recently decreased by 29.61%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDermata Therapeutics does not currently pay a dividend.Dividend GrowthDermata Therapeutics does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.89 News SentimentDermata Therapeutics has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Consumer Staples companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Dermata Therapeutics this week, compared to 1 article on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dermata Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders21.90% of the stock of Dermata Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions8.67% of the stock of Dermata Therapeutics is held by institutions.Read more about Dermata Therapeutics' insider trading history. Receive DRMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dermata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DRMA Stock News HeadlinesDermata Therapeutics (NASDAQ:DRMA) Stock Price Up 0.5% - Should You Buy?October 6, 2026 | americanbankingnews.comDermata Therapeutics announces $3.4M private placementAugust 17, 2026 | msn.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.October 10 at 1:00 AM | Stansberry Research (Ad)DRMA Share News TodayAugust 7, 2026 | uk.investing.comDermata Therapeutics Inc Share Price (DRMA.US)August 7, 2026 | lse.co.ukDermata Therapeutics Insider Trading Activity | NASDAQ:DRMA | BenzingaApril 12, 2026 | benzinga.comDermata Therapeutics (DRMA) price target decreased by 60.00% to 4.08April 9, 2026 | msn.comDermata Therapeutics: Dermata Announces Appointment of Kyra Peckaitis as Vice President, MarketingMarch 10, 2026 | finanznachrichten.deSee More Headlines DRMA Stock Analysis - Frequently Asked Questions How have DRMA shares performed this year? Dermata Therapeutics' stock was trading at $2.32 on January 1st, 2026. Since then, DRMA shares have decreased by 56.0% and is now trading at $1.02. How were Dermata Therapeutics' earnings last quarter? Dermata Therapeutics, Inc. (NASDAQ:DRMA) announced its quarterly earnings data on Tuesday, August, 11th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.55) by $0.19. When did Dermata Therapeutics' stock split? Dermata Therapeutics's stock reverse split on Thursday, May 16th 2024.The 1-15 reverse split was announced on Thursday, May 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Dermata Therapeutics IPO? Dermata Therapeutics (DRMA) raised $21 million in an initial public offering on Friday, August 13th 2021. The company issued 2,571,428 shares at $7.00-$9.00 per share. How do I buy shares of Dermata Therapeutics? Shares of DRMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dermata Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dermata Therapeutics investors own include BIOLASE (BIOL), CNS Pharmaceuticals (CNSP), Esports Entertainment Group (GMBL), Jiuzi (JZXN), Kiora Pharmaceuticals (KPRX), ENDRA Life Sciences (NDRA) and Sonnet BioTherapeutics (SONN). Company Calendar Last Earnings8/11/2026Today10/10/2026Next Earnings (Estimated)11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (11m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 DRMA's financial health is in the Red zone, according to TradeSmith. DRMA has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorConsumer Staples Industry Personal Care Products Sub-IndustryPersonal Care Products Current SymbolNASDAQ:DRMA CIK1853816 Webwww.dermatarx.com Phone858-800-2543FaxN/AEmployees9Year Founded2014Profitability EPS (Trailing Twelve Months)($4.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.56 million Net MarginsN/A Pretax MarginN/A Return on Equity-166.66% Return on Assets-130.13% Debt Debt-to-Equity RatioN/A Current Ratio2.81 Quick Ratio2.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.19 per share Price / Book0.47Miscellaneous Outstanding Shares4,020,000Free Float3,141,000Market Cap$4.10 million OptionableNot Optionable Beta0.66 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:DRMA) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredThis high yielding “gold annuity” is starting to move…Garrett Goggin, a 20+ year gold analyst, has called major moves before: Montage Gold up 2,567%, G2 Goldfields ...Golden Portfolio | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | SponsoredNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dermata Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
